Source comparison
CJC-1295 no DAC & Ipamorelin Benefits: Research Comparison
The following table compares outcomes across different GH secretagogue research protocols based on peer-reviewed preclinical and clinical studies. These are research endpoints, not clinical claims. CJC-1295 no DAC alone 2.5–3.2× baseline +28–35% +5–8% in anima
This comparison does not assign a generated winner or score.
- The following table compares outcomes across different GH secretagogue research protocols based on peer-reviewed preclinical and clinical studies. These are research endpoints, not clinical claims.
- CJC-1295 no DAC alone
- 2.5–3.2× baseline
- +28–35%
- +5–8% in animal models
- Moderate (hydroxyproline +20%)
- Effective monotherapy; short half-life limits duration without repeat dosing
- Ipamorelin alone
- 1.8–2.4× baseline
- +18–25%
- +4–6% in animal models
- Modest (satellite cell activation +15%)
- Selective ghrelin agonism; minimal cortisol/prolactin spike but lower amplitude than GHRH analogs
- CJC-1295 no DAC + Ipamorelin
- 4.5–6.0× baseline
- +55–70%
- +15–22% in animal models
- High (hydroxyproline +45%, myofiber CSA +35%)
- Synergistic dual-pathway activation; physiological pulse pattern with supra-additive GH/IGF-1 response
- GHRP-6 + GHRH analog
- 3.8–5.2× baseline
- +50–65%
- +12–18% in animal models
- High but with cortisol elevation (+30%)
- Effective but less selective; GHRP-6 activates cortisol and prolactin pathways
- MK-677 (oral ghrelin mimetic)
- Sustained 1.5–2.0× baseline
- +40–50%
- +8–12% in human studies
- Moderate with chronic use; ghrelin desensitization risk
- Long half-life (24hr) produces non-pulsatile elevation; different pharmacokinetics